A focused exam app on the Maron and Maron viewpoint: evidence that sudden deaths due to hypertrophic
cardiomyopathy have decreased in athletes and clinically identified patients.
Updated HCM learner module | June 5, 2026
Course progress0%
Start Here
What learners will be able to do
Complete the full learning path: modules, summary, infographics, flashcards, sources, feedback, and final exam.
Learner registration
Enter the learner's information before starting. Results are stored in this browser and can be exported for upload to a roster or LMS.
Recognize the historical concern
Explain why HCM became highly visible as a cause of sudden death in young active people and athletes.
Interpret changing event data
Compare earlier registry findings with more recent athlete sudden-death surveys reporting fewer HCM events.
Apply prevention concepts
Connect selective sports restriction, risk stratification, and primary-prevention ICD therapy to falling sudden-death rates.
Source basis: This app is adapted for education from Maron and Maron,
"Evidence Supporting Decrease in Sudden Deaths Due to Hypertrophic Cardiomyopathy: Athletes and Patients."
It is educational only and is not a diagnostic device, eligibility clearance tool, ICD recommendation, or substitute
for specialist cardiology judgment, shared decision-making, local policy, or full guideline review.
Updated HCM learner module: This version includes the full learner path: teaching modules,
high-yield summary, improved visual infographics, flashcards, instructor-approved sources, feedback, and final exam.
New In This Learner Version
More than a module reader
The HCM lesson now includes visual review, active recall, source transparency, and feedback reporting before the final exam.
Select any module or activity card to jump directly to that screen. You can also scroll down or use Page Down to move through the overview.
Module 1
HCM and sudden death: the historical concern
For decades, hypertrophic cardiomyopathy was regarded as a prominent cause of unexpected sudden death in young active people.
The paper revisits that reputation and asks whether contemporary strategies have changed the risk landscape.
Sudden deaths in athletes were once attributed to overtraining but later linked to underlying cardiovascular disease.
HCM and arrhythmogenic right ventricular cardiomyopathy became major recognized causes in athlete sudden death discussions.
The authors focus on two settings: undiagnosed athletes in the community and clinically identified HCM patients.
The paper argues that prevention strategies have contributed to lower event rates.
Core thesis
HCM sudden deaths appear to have decreased in both athletes and identified patients, likely reflecting modern screening, eligibility decisions, risk stratification, and ICD therapy.
Knowledge check
What is the paper's main clinical question?
Module 2
Athlete evidence: older and newer data do not look the same
Evidence set
What it found
Teaching point
Older U.S. National Sudden Death in Athletes Registry
HCM was the single most common cause among major cardiovascular diagnoses, accounting for 35% of events in a large postmortem survey.
These data included years before widespread screening and eligibility initiatives.
Recent athlete surveys
Five recent surveys from the United States, United Kingdom, and Denmark counted 49 HCM-athlete deaths over 62 study-years, averaging less than 1 per year.
Recent datasets suggest lower HCM death frequency than older registry experience.
NCAA and high-school data
Recent cohorts show small absolute numbers of HCM deaths compared with historical registry totals.
Event trends may reflect improved detection, restriction of higher-risk athletes, and changing ascertainment.
The authors emphasize that the apparent decline is probably multifactorial and difficult to prove prospectively, but they argue the trend is clinically meaningful.
Older eraLess screening, more occult disease
DetectionPreparticipation identification of HCM
EligibilitySelective restriction from intense competition
Recent dataLower observed HCM-athlete deaths
Module 3
Eligibility decisions and the sports environment
Why competition matters
Intense competitive sport can create unpredictable autonomic, metabolic, and ischemic stressors that may lower thresholds for lethal tachyarrhythmias in susceptible HCM patients.
Selective restriction
The paper supports the long-standing AHA/ACC consensus approach advising prudent restriction, especially for HCM athletes with obstruction, symptoms, or risk markers.
Current debate
The authors challenge an emerging liberalized eligibility narrative that prioritizes shared decision-making and personal liberty over safety in all cases.
Knowledge check
Which HCM athlete features does the paper highlight as especially relevant to selective restriction?
Module 4
ICD primary prevention changed the patient story
Before ICD prevention
For much of HCM history, clinicians had limited tools and often learned of sudden death only after it occurred. Antiarrhythmic drugs were ineffective for preventing these events.
After ICD adoption
The implantable cardioverter-defibrillator became accepted internationally for high-risk HCM patients. The paper describes ICD therapy as a paradigm breakthrough in changing disease course.
Reported performance
The authors cite an AHA/ACC risk strategy with high sensitivity for anticipating and preventing sudden death and a low device-failure rate, while noting that more than 1000 HCM patients worldwide have survived life-threatening ventricular tachyarrhythmias due to ICD therapy.
High-risk HCMConsider ICD prevention
Appropriate shockTerminated VT/VF
No ICD selectedVery low observed arrhythmic SD in cited cohort
Overall mortalityReported as low in modern HCM care
ICD decisions are not automatic. They depend on risk stratification, patient context, device risks, and expert conversation.
Module 5
Risk strategy and patient conversations
The viewpoint contrasts two approaches used in practice: the AHA/ACC clinical-marker strategy and the ESC mathematical risk-score model.
Both support conversations about risk, but they emphasize different performance characteristics.
The AHA/ACC algorithm uses accepted clinical risk markers and is described by the authors as highly sensitive for identifying patients who may benefit from ICD protection.
The ESC model uses a formula with multiple clinical variables and is favored by many European cardiologists for higher specificity and limiting device overuse.
Risk categories can help structure discussions with patients and families, but they do not replace judgment.
The paper concludes that eligibility guidelines and ICD prevention deserve continued attention and support.
Clinical balance
Prevention means avoiding sudden death while also avoiding unnecessary restriction, device complications, and oversimplified one-size-fits-all decisions.
DetectIdentify HCM and risk markers
DiscussExplain sport and SD risk context
ProtectUse ICD prevention when indicated
IndividualizeBalance safety, values, and harms
FollowReassess over time
Summary
High-yield HCM sudden death prevention points
Use this for quick review before flashcards or the exam.
Historical concern
HCM became highly visible as a cause of sudden death in young active people and athletes.
Event trends
The viewpoint argues that contemporary initiatives are associated with fewer HCM sudden-death events.
Athlete prevention
Screening, recognition, and selective restriction of higher-risk athletes may contribute to lower observed athlete deaths.
ICD prevention
Primary-prevention ICD therapy changed the story for selected high-risk HCM patients.
Risk strategy
AHA/ACC clinical markers and ESC risk modeling are different ways to structure risk conversations.
Clinical caveat
Eligibility and ICD decisions require specialist judgment, shared decision-making, and patient context.
Infographics
Visual teaching infographics
Use these visual summaries on screen before flashcards and the exam. Printing is optional.
HCM prevention map
From hidden risk to protected patient
Hidden HCMRisk may be unrecognized
DetectClinical evaluation and screening
Goal
Prevent sudden deathwithout unnecessary harm
Sport decisionRestrict higher-risk exposure
ICD protectionTerminate VT/VF when indicated
Follow-upReassess risk over time
Prevention arc
How the HCM patient story changed
1Recognize risk
HCM becomes visible in athlete sudden-death discussions.
2Find disease earlier
Screening and evaluation identify some affected athletes before events.
3Reduce exposure
Higher-risk athletes may be restricted from intense competition.
4Protect selected patients
ICDs can terminate life-threatening VT/VF in high-risk patients.
Evidence pattern
Older registry signal vs recent surveys
Older registry era
HCM highly visible
Older postmortem registry experience made HCM a leading concern in athlete sudden death.
then
Recent surveys cited
Fewer HCM-athlete deaths
The viewpoint emphasizes smaller recent counts and a likely multifactorial decline.
Clinical conversation
Risk strategy is a conversation, not a single switch
HCM decisionPrevent sudden death while avoiding unnecessary harm
Risk markersSymptoms, obstruction, VT, scar, syncope, family history
Sport contextIntensity, setting, emergency plan, athlete goals